Dr. Giselle Sholler, principal investigator and pediatric oncologist from Vermont Cancer Center, presented important information regarding the newly opened "Phase 1 Trial of TPI 287 as a Single Agent and in Combination with Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma." This presentation was intended for parents and caregivers of children with refractory or recurrent neuroblastoma and medulloblastoma. Dr. Sholler provided an overview of the preclinical research leading up to the trial. She also discussed the rationale behind the trial and the eligibility requirements. Parents of children that have participated in this trial were also available to share their experiences. The presentation was followed with a question and answer session. This presentation and question and answer session was originally published on Wednesday, August 26, 2009 at 12:00PM CST.
Welcome to our website. It is a place for you to find answers and ask questions. One of the primary goals of the Neuroblastoma Foundation is to ensure that parents, patients and health care professionals find the information they need to make the best treatment decisions possible for children and adults affected by neuroblastoma. There is a vast amount of information throughout the internet, much of which is encapsulated in medical jargon that is so complex that even many medical professionals have difficulty in interpreting its meaning. We are here to help to decipher this information and to make sure you (and your oncologist) understand exactly what it means to you. From treatment decisions to side effects we have parents and experts that have experienced it all and are willing to distill it for you.